300289SZSE
🚨 Material Event

Board of Directors' Explanation on Dilution of Immediate Returns from the Transaction and Related Remedial Measures

Lideman Co., Ltd.··4 pages

✨ AI Summary

Beijing Lideman Biochemical Pharmaceutical Co., Ltd. will acquire 61.50% of Beijing Saishang Xiangrui Biological Products Co., Ltd. for cash. This transaction may dilute immediate returns per share. The company outlines measures to mitigate this risk, including integration, improved governance, and a refined dividend policy, with commitments from management and the controlling shareholder.

Summary generated by AI · Always verify with source document

Full Translation

AI Translation· gemini_document

Beijing Lideman Biochemical Pharmaceutical Co., Ltd. (hereinafter referred to as the "Company" or "Listed Company") intends to acquire 235,040,700 shares of Beijing Saishang Xiangrui Biological Products Co., Ltd. (hereinafter referred to as "Saishang Xiangrui") held by Hainan Baimai Investment Co., Ltd., Hainan Saishang Baijia Hui Technology Development Co., Ltd., and Nanjing Baijiarui Enterprise Management Consulting Partnership (Limited Partnership) (representing 61.50% of the issued share capital of Saishang Xiangrui) (hereinafter referred to as the "Transaction") through cash payment.

The Company's Board of Directors provides the following explanation on the dilution of immediate returns from the Transaction and related remedial measures:

In accordance with the "Opinions of the General Office of the State Council on Further Strengthening the Protection of the Legal Rights and Interests of Small and Medium Investors in the Capital Market" (Guo Ban Fa [2013] No. 110), the "Opinions of the State Council on Further Promoting the Healthy Development of the Capital Market" (Guo Fa [2014] No. 17), and the "Guiding Opinions on Matters Related to the Dilution of Immediate Returns from Issuance, Refinancing, and Major Asset Restructuring" (CSRC [2015] No. 31), the Company has conducted a thorough, prudent, and objective analysis of the impact of the Transaction on the dilution of immediate returns.

I. Impact of the Transaction on Earnings Per Share

According to the financial statements of the listed company and the "Review Report on Pro Forma Financial Statements" (Rongcheng Review Zi [2026]100Z0014) issued by Rongcheng Certified Public Accountants (Special General Partnership), the net profit attributable to parent company shareholders and basic earnings per share before and after the transaction are as follows:

Project2025/12/31 / 2025 Fiscal Year2024/12/31 / 2024 Fiscal Year
Before TransactionPro Forma (After Transaction)
Net Profit Attributable to Parent Company Shareholders (RMB 10,000)-2,298.318,977.16
Basic Earnings Per Share (RMB/share)-0.040.15

Sign in to read the full translation

Free accounts get 10 full releases per month. Pro subscribers get unlimited access.